Muscle Spasticity - Pipeline Review, H2 2015 report provides comprehensive information on the therapeutic development for Muscle Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasticity and special features on late-stage and discontinued projects.
Companies mentioned in this report are Daewoong Pharmaceutical Co., Ltd., Ipsen S.A., OBI Pharma, Inc., Sanochemia Pharmazeutika AG, Sun Pharma Advanced Research Company Ltd
Get a copy of this report http://bit.ly/1W4Lu6f . This is a premium report price at US$2000 for a single user PDF license
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
· The report summarizes all the dormant and discontinued pipeline projects
· A review of the Muscle Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
· Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
· A detailed assessment of monotherapy and combination therapy pipeline projects
· Coverage of the Muscle Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
· Latest news and deals relating related to pipeline productsThe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.